Paraneoplastic movement disorders

Česká verze

Authors: O. Shabatiuk ^1,2; J. Necpál ^1,2
Authors place of work: Neurologické oddelenie, Nemocnica, Zvolen, a. s. ¹; Centrum pre liečbu parkinsonizmu, a extrapyramídových porúch, Nemocnica Zvolen, a. s. ²
Published in the journal: Cesk Slov Neurol N 2025; 88(3): 160-167
Category: Přehledný referát
doi: https://doi.org/10.48095/cccsnn2025160

Summary

Paraneoplastic neurological syndromes (PNS) with movement disorders represent a broad group of disorders, which is still growing due to discovery new autoantibodies damaging the nervous system. However, in contrast to neurodegenerative diseases, these disorders can be potentionally treatable. This review brings an overview of the clinical picture of a particular PNS, as well as instructions on how to diagnose and treat them in clinical practice.

Keywords:

Autoantibodies – paraneoplastic syndromes – movement disorders

Zdroje

1. Schulz P, Prüss H. „Hirnsymptome bei Carcinomatose“ – Hermann Oppenheim and an early description of a paraneoplastic neurological syndrome. J Hist Neurosci 2015; 24 (4): 371–377. doi: 10.1080/0964704X.2015.1021120.

2. Graus F, Vogrig A, Muñiz-Castrillo S et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8 (4): e1014. doi: 10.1212/NXI.0000000000001014.

3. Sophie LD, Harald P. Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors. Neurotherapeutics 2022; 19 (3): 848–863. doi: 10.1007/s13311-022-01184-0.

4. Iorio R, Spagni G, Masi G. Paraneoplastic neurological syndromes. Semin Diagn Pathol 2019; 36 (4): 279–292. doi: 10.1053/j.semdp.2019.06.00.

5. Vogrig A, Muñiz-Castrillo S, Desestret V et al. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord 2020; 13: 1756286420932797. doi: 10.1177/1756286420932797.

6. Balint B, Vincent A, Meinck HM et al. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain 2018; 141 (1): 13–36. doi: 10.1093/brain/awx189.

7. Hsieh PC, Wu YR. Diagnosis and clinical features in autoimmune-mediated movement disorders. J Mov Disord 2022; 15 (2): 95–105. doi: 10.14802/jmd.21077.

8. Wu X, Wang H, Xu G et al. Anti-CV2 autoimmune encephalitis with Parkinson-like symptoms and bilateral leukoencephalopathy – a case report. Front Neurol 2019; 10: 1064. doi: 10.3389/fneur.2019.01064.

9. Michelle FD, Naga K, Mahmoud E et al. Paraneoplastic neurological syndromes: clinical presentations and management. Ther Adv Neurol Disord 2020; 14: 1756286420985323. doi: 10.1177/1756286420985323.

10. Li Ch, Wang X, Sun L et al. Anti-SOX1 antibody-positive paraneoplastic neurological syndrome presenting with Lambert-Eaton myasthenic syndrome and small cell lung cancer: a case report. Thorac Cancer 2020; 11 (2): 465–469. doi: 10.1111/1759-7714.13290.

11. Gupta HV, Gervais C, Ross MA et al. Purkinje cell cytoplasmic antibody (PCA-2) -related chorea-dystonia syndrome. Tremor Other Hyperkinet Mov 2016; 6: 420. doi: 10.7916/D8SX6DFJ.

12. Sun Y, Qin X, Huang D et al. Anti-amphiphysin encephalitis: expanding the clinical spectrum. Front Immunol 2023; 14: 1084883. doi: 10.3389/fimmu.2023.1084883.

13. Simard C, Vogrig A, Joubert B et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm 2020; 7 (3): e699. doi: 10.1212/NXI.0000000000000699.

14. Deac S, Stana MM, Havasi AD et al. Paraneoplastic cerebellar degeneration associated with anti-Yo antibodies in an ovarian cancer case: a case report. Gynecol Oncol Rep 2020; 35: 100695. doi: 10.1016/j.gore. 2020.100695.

15. Ortega Suero G, Sola-Valls N, Escudero D et al. Anti-Ma and anti-Ma2-associated paraneoplastic neurological syndromes. Neurologia 2018; 33 (1): 18–27. doi: 10.1016/j.nrl.2016.05.010.

16. Peter E, Do LD, Hannoun S et al. Cerebellar ataxia with anti-DNER antibodies: outcomes and immunologic features. Neurol Neuroimmunol Neuroinflamm 2022; 9 (5): e200018. doi: 10.1212/NXI.0000000000200018.

17. Mandel-Brehm C, Dubey D, Kryzer TJ et al. Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 2019; 381 (1): 47–54. doi: 10.1056/NEJMoa1816721.

18. Laurido-Soto O, Brier MR, Simon LE et al. Patient characteristics and outcome associations in AMPA receptor encephalitis. J Neurol 2019; 266 (2): 450–460. doi: 10.1007/s00415-018-9153-8.

19. Höftberger R, Sonderen A, Leypoldt F et al. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology 2015; 84 (24): 2403–2412. doi: 10.1212/WNL.0000000000001682.

20. Guo K, Liu X, Gong X et al. Autoimmune encephalitis with mGluR5 antibodies: a case series from China and review of the literature. Front Immunol 2023; 14: 1146536. doi: 10.3389/fimmu.2023.1146536.

21. Damato V, Balint B, Kienzler AK et al. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord 2018; 33 (9): 1376–1389. doi: 10.1002/mds.27446.

22. Miao A, Shi Y, Xiang J et al. Using EEG and MEG to characterize extreme delta brush in a patient with anti-NMDA receptor encephalitis. BMC Neurology 2021; 21 (1): 134. doi: 10.1186/s12883-021-02157-0.

23. Thomas L. Treatment and prognosis of anti-NMDA receptor encephalitis. [online]. Dostupné z: https: //www.news-medical.net/health/Treatment-and-Prognosis-of-Anti-NMDA-Receptor-Encephalitis.aspx.

24. Shivaram S, Nagappa M, Seshagiri DV et al. Clinical profile and treatment response in patients with CASPR2 antibody-associated neurological disease. Ann Indian Acad Neurol 2021; 24 (2): 178–185. doi: 10. 4103/aian.AIAN_574_20.

25. Khojah O, Makkawi S, Alghamdi S. Anti-mGluR1 encephalitis: case illustration and systematic review. Front Neurol 2023; 14: 1142160. doi: 10.3389/fneur.2023. 1142160.

26. Spatola M, Petit-Pedrol M, Simabukuro MM et al. Investigations in GABAA receptor antibody-associated encephalitis. Neurology 2017; 88 (11): 1012–1020. doi: 10.1212/WNL.0000000000003713.

27. Wang H, Chin JH, Fang B et al. Autoimmune glial fibrillary acidic protein astrocytopathy manifesting as subacute meningoencephalitis with descending myelitis: a case report. BMC Neurology 2020; 20 (1): 443. doi: 10.1186/s12883-020-02021-7.

28. Dumonceau AG, Ameli R, Rogemond V et al. Glial fibrillary acidic protein autoimmunity: a French cohort study. Neurology 2022; 98 (6): e653–e668. doi: 10.1212/WNL.0000000000013087.

29. Naasan G, Irani SR, Bettcher BM et al. Episodic bradycardia as neurocardiac prodrome to voltage-gated potassium channel complex/leucine-rich, glioma inactivated 1 antibody encephalitis. JAMA Neurol 2014; 71 (10): 1300–1304. doi: 10.1001/jamaneurol.2014.1234.

30. Lin J, Zhu M, Mao X et al. Anti-dipeptidyl-peptidase-like protein 6 encephalitis with pure cerebellar ataxia: a case report. BMC Neurology 2022; 22 (1): 242. doi: 10.1186/s12883-022-02769-0.

31. Hara M, Helena Ariño H, Petit-Pedrol M et al. DPPX antibody-associated encephalitis. Neurology 2017; 88 (14): 1340–1348. doi: 10.1212/WNL.0000000000003796.

32. Swayne A, Tjoa L, Broadley S et al. Anti glycine receptor antibody related disease: a case series and literature review. Eur J Neurol 2018; 25 (10): 1290–1298. doi: 10.1111/ene.13721.

33. Zhang YH, Ni Y, Gao YN et al. Anti-IgLON5 disease: a novel topic beyond neuroimmunology. Neural Regen Res 2023; 18 (5): 1017–1022. doi: 10.4103/1673-5374.355742.

34. Grüter T, Möllers FE, Tietz A et al. Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain 2023; 146 (2): 600–611. doi: 10.1093/brain/awac090.

35. Fu Y, Zou X, Liu L. Epileptic seizures and right-sided hippocampal swelling as presenting symptoms of anti-IgLON5 disease: a case report and systematic review of the literature. Front Neurol 2022; 13: 800298. doi: 10.3389/fneur.2022.800298.

36. Garza M, Piquet AL. Update in autoimmune movement disorders: newly described antigen targets in autoimmune and paraneoplastic cerebellar ataxia. Front Neurol 2021; 12: 683048. doi: 10.3389/fneur.2021. 683048.

37. Klötzsch C, Böhmert M, Hermann R et al. Anti-Homer-3 antibodies in cerebrospinal fluid and serum samples from a 58-year-old woman with subacute cerebellar degeneration and diffuse breast adenocarcinoma. Neurol Res Pract 2022; 4 (1): 29. doi: 10.1186/s42466-022-00194-9.

38. Zekeridou A, Kryzer T, Guo Y et al. Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunity. Neurology 2019; 93 (8): e815–e822. doi: 10.1212/WNL.0000000000007971.

39. Vilaseca A, González V, Auger C et al. Teaching neuroimage: paraneoplastic cerebellar degeneration and antibodies to TRIM 9 and 67 secondary to melanoma. Neurology 2023; 101 (16): e1652–e1653. doi: 10.1212/WNL.0000000000207702.

40. Gresa-Arribas N, Planagumà J, Petit-Pedrol M et al. Human neurexin-3a antibodies associate with encephalitis and alter synapse development. Neurology 2016; 86 (24): 2235–2242. doi: 10.1212/WNL.00000000000 02775.

41. Miske R, Scharf M, Borowski K et al. Septin-3 autoimmunity in patients with paraneoplastic cerebellar ataxia. J Neuroinflammation 2023; 20 (1): 88. doi: 10.1186/s12974-023-02718-9.

42. Dai X, Kuang L, Feng L et al. Anti-dopamine receptor 2 antibody-positive encephalitis in adolescent. Front Neurol 2020; 11: 471. doi: 10.3389/fneur.2020.00471.

43. Marques-Matos C, Melo C, Sampaio M et al. Child neurology: treatable bilateral striatal lesions related to anti-dopamine 2 receptor autoimmunity. Neurology 2018; 91 (2): 98–101. doi: 10.1212/WNL.0000000000005774.

44. Loehrer PA, Timmermann L, Pehl A et al. Rhombencephalitis associated with isolated Zic4-antibodies in paraneoplastic cerebellar degeneration: a case report. BMC Neurology 2020; 20 (1): 208. doi: 10.1186/s12883-020-01788-z.

45. Garceza D, Marquesa J, Fernandesa M et al. ATP1A3: an unusual antigen to consider in patients with subacute ataxia and vertical gazepalsy. Mult Scler Relat Disord 2020; 43: 102160. doi: 10.1016/j.msard.2020.102160.

46. Kather A, Holtbernd F, Brunkhorst R et al. Anti-SEZ6L2 antibodies in paraneoplastic cerebellar syndrome: case report and review of the literature. Neurol Res Pract 20221; 4 (1): 54. doi: 10.1186/s42466-022-00218-4.

47. Gövert F, Leypoldt F, Junker R et al. Antibody-related movement disorders – a comprehensive review of phenotype-autoantibody correlations and a guide to testing. Neurol Res Pract 2020; 2: 6. doi: 10.1186/s42466-020-0053-x.

48. Balint B. Relevance of antibody testing in movement disorders. Mov Disord Clin Pract 2023; 10 (Suppl 2): S32–S35. doi: 10.1002/mdc3.13772.

49. Balint B, Bhatia KP, Dalmau J. „Antibody of Unknown Significance“ (AUS): the issue of interpreting antibody test results. Mov Disord 2021; 36 (7): 1543–1547. doi: 10.1002/mds.28597.

50. Marsili L, Marcucci S, LaPorta J et al. Paraneoplastic neurological syndromes of the central nervous system: pathophysiology, diagnosis, and treatment. Biomedicines 2023; 11 (5): 1406. doi: 10.3390/biomedicines11051406.

51. Jiraporn J, Pritikanta P, Smathorn T et al. Paraneoplastic neurological syndrome: an evolving story. Neurooncol Pract 2021; 8 (4): 362–374. doi: 10.1093/nop/npab002.

52. Harald P. Autoantibodies in neurological disease. Nat Rev Immunol 2021; 21 (12): 798–813. doi: 10.1038/ s41577-021-00543-w.